Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03335488
Recruitment Status : Recruiting
First Posted : November 7, 2017
Last Update Posted : January 19, 2021
Sponsor:
Information provided by (Responsible Party):
Horizon Pharma Ireland, Ltd., Dublin Ireland ( Horizon Therapeutics, LLC )

Brief Summary:
This is a randomized, controlled, open-label parallel arm study to assess the safety, tolerability, pharmacokinetics and ammonia control, of RAVICTI® as compared to NaPBA in urea cycle disorder subjects not currently or previously chronically treated with phenylacetic acid (phenylacetate; PAA) prodrugs. The study design will include: 1) Baseline Period; 2) Initial Treatment Period; 3) a RAVICTI only Transition Period 4) a RAVICTI only Maintenance Period; and 5) a RAVICTI only Safety Extension Period. The study will run for approximately 25 weeks.

Condition or disease Intervention/treatment Phase
Urea Cycle Disorder Drug: RAVICTI Drug: NaPBA Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Controlled, Open-Label Parallel Arm study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders
Actual Study Start Date : February 20, 2018
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : March 2023


Arm Intervention/treatment
Experimental: Arm 1, RAVICTI
Used for Baseline, Treatment, Transition, Maintenance, and Safety. Dosing will be based on participants disease and treatment status at entry to the study. RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose.
Drug: RAVICTI
RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
Other Names:
  • Glycerol phenylbutyrate
  • GPB
  • HPN-100

Active Comparator: Arm 2, NaPBA (sodium phenylbutyrate)

Used for Baseline and Treatment. Sodium Phenylbutyrate (NaPBA). Dosing will be based on participants disease and treatment status at entry to the study.

  • NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose
  • NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose
Drug: NaPBA
  • NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose
  • NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose
Other Name: Sodium phenylbutyrate




Primary Outcome Measures :
  1. Rate of Treatment Success [ Time Frame: Week 4 ]

    A subject will be considered a Treatment Success for the assigned treatment arm if the subject has not experienced an unprovoked hyperammonemic crisis (HAC) (i.e., a HAC that cannot be attributed to one or more specific precipitating factors such as infection, intercurrent illness, diet noncompliance, treatment noncompliance, etc.) on the assigned treatment and has met at least 2 of the following 3 criteria:

    • Has absolute values at the 3 time points (pre-dose, after dose at 4 hours and 8 hours) of plasma ammonia levels which do not exceed ULN at the Week 4(End of Initial Treatment Period visit)
    • Has normal (≤ ULN) glutamine levels at the Week 4 (End of Initial Treatment Period visit at the time point Zero Hour.
    • Has normal (≤ ULN) essential amino acids including branched chain amino acid levels (threonine, phenylalanine, methionine, lysine, leucine, isoleucine, histidine, valine) at the End of Initial Treatment Period visit at time point Zero Hour.


Secondary Outcome Measures :
  1. Annualized Rate of Hyperammonemic Crisis (HAC) [ Time Frame: Week 25 ]
    Hyperammonemic Crisis (HAC) will be captured throughout the study.

  2. Amino Acid Assessment [ Time Frame: Day 1, Week 1, 2, 3, 4, 5, 9, 13, 17, 21, 25 ]
    The amino acid panel will include ornithine, aspartic acid, serine, threonine, glutamic acid, asparagine, proline, glutamine, alanine, glycine, valine, citrulline, methionine, cystine, leucine, isoleucine, phenylalanine, tyrosine, lysine, arginine, taurine, phosphoserine, phosphoethanolamine, alpha-aminobutyric acid, 1-methylhistidine, histidine, 3-methylhistidine, and argininosuccinate.

  3. Rate of Drug Discontinuations Due to Any Reasons [ Time Frame: Baseline through Week 4 ]
  4. Rate of Drug Discontinuations Due to Adverse Events [ Time Frame: Baseline through Week 25 ]
  5. Palatability of Study Drug (Hedonic Scale) [ Time Frame: Week 4 , Week 5 (End of transition period for participant on NaPBA arm) ]
    The Hedonic scale is a validated scale developed to assess palatability of medications. Participants (or parents or caregivers) are asked to rate the palatability of RAVICTI (glycerol phenylbutyrate) Oral Liquid and NaPBA based on the participant's reactions. There are 5 smiley faces to choose from. Happy face = likes very much through sad face = dislikes very much.

  6. Clinical Global Impression (CGI) Scales Severity (Investigator Only) [ Time Frame: Baseline, Week 13 and 25 ]
    Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of rating, relative to clinician's past experience with patient's who have the same diagnosis. Rating scale is 1 = normal not ill to 7 = extremely ill.

  7. Clinical Global Impression (CGI) Scales Improvement (Investigator Only) [ Time Frame: Baseline, Week 13 and 25 ]
    The CGI improvement scale is a 7 point scale that shows improvement. This scale requires the investigator to assess how much of the participant's illness has improved or worsened relative to a Baseline state. 1= very much improved to 7= very much worse.

  8. Neuropsychological Checklists Child Behavior (CBCL) [ Time Frame: Baseline, Week 13 and 25 ]
    CBCL is a questionnaire by which parents rate a child's problem behaviors and competencies. The preschool checklist (CBCL/1.5 to 5) is intended for use with children aged 18 months to 5 years. The school-age version (CBCL/6-18) is for children aged 6 to 18 years. It is used as a diagnostic tool for a variety of behavioral and emotional problems.

  9. Neuropsychological Checklist Adult Behavior (ABCL) [ Time Frame: Baseline, Week 13 and 25 ]
    The ABCL is a questionnaire used to obtain information about the individual's adaptive functioning and problems. It is intended for use with adults aged 19 to 59 years. This is a diagnostic tool for a variety of behavioral and emotional problems. It is completed by an observer who knows the individual well.

  10. Neuropsychological Assessment Adult Self Report (ASR) [ Time Frame: Baseline, Week 13 and 25 ]
    Assessment adult self report (ASR) is a questionnaire used to obtain information about the individual's adaptive functioning and problems. It will be completed by those participants able to self-complete the form.

  11. EQ-5D-5L Health Status Quality of Life [ Time Frame: Baseline,Week 4, 13 and 25 ]
    The EQ-5D-5L provides a simple descriptive profile and a single index value for health status that can be used in the clinical and economic evaluation of health care as well as in population health surveys. It is designed for self-completion by participants or caregivers of subjects aged ≥12 years. There are 5 values, mobility, self care, usual activities, pain/discomfort, anxiety/depression. The questionnaire includes 5 levels, no problems, slight problems, moderate problems, severe problems, and extreme problems which are used for assessment.

  12. Plasma Concentration of Phenylbutyric Acid (PBA) [ Time Frame: Week 4 ]
    Blood samples will be collected for the assessment of the plasma level of PBA and plasma concentration levels will be summarized using descriptive statistics.

  13. Plasma Concentration of Phenylacetic Acid (PAA) [ Time Frame: Week 4 ]
    Blood samples will be collected for the assessment of the plasma level of PAA and plasma concentration levels will be summarized using descriptive statistics.

  14. Plasma Concentration of Phenylacetylglutamine (PAGN) [ Time Frame: Week 4 ]
    Blood samples will be collected for the assessment of plasma level of PAGN and plasma concentration levels will be summarized using descriptive statistics.

  15. Urinary Excretion of Phenylacetylglutamine (PAGN) [ Time Frame: Week 4 ]
    Urine samples will be collected at hours 0 and 8 for the assessment of urinary excretion of PAGN.

  16. Rate of Adverse Events [ Time Frame: Baseline through Week 25 and 30 days post last dose for SAEs ]
    Treatment Emergent Adverse Events will be summarized by treatment received.

  17. Drug preference (NaPBA arm only) [ Time Frame: Week 5 ]
    Measures which drug is preferred. Participant is queried directly however for younger children, the parent or legal guardian can report on behalf of the child if more appropriate.

  18. Plasma Ammonia Level [ Time Frame: Day 1, Week 1, 2, 3, 4, 5, 9, 13, 17, 21, 25 ]
    Plasma ammonia will be analyzed on Day 1, Week 1, 2, 3, 4, 5, 9, 13, 17, 21, 25.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent given by the subject or the subject's parent/legal guardian for those under 18 years of age or the age of consent by local regulation.
  • Male and female subjects with a suspected or confirmed UCD diagnosis of any subtype, except NAGS deficiency.
  • Suspected diagnosis is defined as having experienced a HAC or a documented high ammonia of >=100 µmol/L
  • Confirmed diagnosis is determined via enzymatic, biochemical, or genetic testing.

    • Requires nitrogen-binding agents according to the judgment of the Investigator
    • Birth and older.
    • All females of childbearing potential and all sexually active males must agree to use an acceptable method of contraception from signing the informed consent throughout the study and for 30 days after the last dose of study drug. Acceptable forms of contraception are (oral, injected, implanted or transdermal), tubal ligation, intrauterine device, hysterectomy, vasectomy, or double barrier methods. Abstinence is an acceptable form of birth control, though appropriate contraception must be used if the subject becomes sexually active.

Exclusion Criteria:

  • Subject has received chronic treatment with an oral phenylbutyrate (RAVICTI, NaPBA, Pheburane, or other) longer than 14 consecutive days within one year prior to enrollment.
  • Temporary use of NaPBA for acute management of a hyperammonemic crisis in the past is acceptable.

    • Any concomitant illness (e.g., malabsorption or clinically significant liver or bowel disease) which would preclude the subject's safe participation, as judged by the Investigator.
    • Has undergone liver transplantation, including hepatocellular transplant.
    • Subjects on NaBz at Baseline will be excluded if they are viewed by the Investigator as being unable to undergo NaBz transition to a PAA prodrug during the Initial Treatment Period.
    • Known hypersensitivity to PBA or any excipients of the NaPBA/PBA formulations.
    • Pregnant or breast-feeding patients. Women of childbearing potential must have a pregnancy test performed at the Baseline Visit prior to the start of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03335488


Contacts
Layout table for location contacts
Contact: HorizonTherapeutics 866-479-6742 clinicaltrials@horizontherapeutics.com

Locations
Layout table for location information
United States, Florida
University of Florida (UF) - Shands Hospital Recruiting
Gainesville, Florida, United States, 32610-0214
Contact: Roberto Zori, MD    352-273-7763    zorirt@peds.ufl.edu   
Principal Investigator: Roberto Zori, MD         
United States, New York
Mount Sinai School of Medicine Recruiting
New York, New York, United States, 10029
Contact: George Diaz, M.D., PhD.    212-241-0858    George.Diaz@mssm.edu   
Principal Investigator: George Diaz, M.D., PhD.         
United States, Ohio
University Hospitals Case Medical Center Recruiting
Cleveland, Ohio, United States, 44106-6005
Contact: Dr. Jirair Bedoyan, MD    216-844-7124    Jirair.Bedoyan@UHhospitals.org   
Principal Investigator: Dr. Jirair Bedoyan, MD         
United States, Pennsylvania
Children's Hospital of Pittsburgh of UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Dr. Gerard Vockley, MD, PhD    412-692-7530    Jennifer.baker@chp.edu   
Contact: Jennifer Baker    412-692-7530    Jennifer.baker@chp.edu   
Principal Investigator: Dr. Gerard Vockley, MD, PhD         
United States, Texas
University of Texas, Southwestern Medical Centre Recruiting
Dallas, Texas, United States, 753908565
Contact: Markey McNutt, MD, PhD    214-648-1814    Markey.McNutt@UTSouthwestern.edu   
Principal Investigator: Markey McNutt, MD, PhD         
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Dr. Nicola Longo, M.D., PhD.    801-587-3605    Nicola.Longo@hsc.utah.edu   
Contact: Carrie Bailey    801 587 3605    Carrie.Bailey@hsc.utah.edu   
Principal Investigator: Dr. Nicola Longo, M.D., PhD.         
Belgium
Cliniques Universitaires Saint-Luc Withdrawn
Brussels, Belgium, 1200
Italy
Azienda Ospedaliera Universitaria Di Padova, U.O.C. Malattie Metaboliche Ereditarie, Dipartimento della Salute della Donna e del Bambino Recruiting
Padua, Veneto, Italy, 35128
Contact: Alberto Burlina, MD    +39 049 821 3569    alberto.burlina@unipd.it   
Principal Investigator: Alberto Burlina, MD         
Bambino Gesù Children's Research Hospital Recruiting
Rome, Italy, 00165
Contact: Diego Martinelli, MD, PhD    +39 06/68592275    diego.martinelli@opbg.net   
Principal Investigator: Dr. Diego Martinelli, MD, PhD         
Spain
Hospital Materno-Infantil (HRU Carlos Haya) Recruiting
Málaga, Andalucia, Spain, 29006
Contact: Dr. Javier Blasco-Alonso, MD    34 951 29 21 91    javierblascoalonso@yahoo.es   
Contact: Almudena Frias    34 951 29 21 91      
Principal Investigator: Dr. Javier Blasco-Alonso         
Hospital Clinico Universitario de Santiago Withdrawn
Santiago de Compostela, Galicia, Spain, 15706
Hospital Universitario de Cruces Completed
Barakaldo, Vizcaya, Spain, 48903
Switzerland
Universitätsspital, Inselspital Bern Completed
Bern, Switzerland, 3010
University Children's Hospital Withdrawn
Zurich, Switzerland, 75, 8032
Sponsors and Collaborators
Horizon Therapeutics, LLC
Investigators
Layout table for investigator information
Study Director: Colleen Canavan, BS Horizon Therapeutics, LLC
Layout table for additonal information
Responsible Party: Horizon Therapeutics, LLC
ClinicalTrials.gov Identifier: NCT03335488    
Other Study ID Numbers: HPN-100-021
2015-000075-27 ( EudraCT Number )
First Posted: November 7, 2017    Key Record Dates
Last Update Posted: January 19, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Horizon Pharma Ireland, Ltd., Dublin Ireland ( Horizon Therapeutics, LLC ):
Urea
Hyperammonemic crisis (HAC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Urea Cycle Disorders, Inborn
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
4-phenylbutyric acid
Glycerol
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents